[This website is currently under construction, CARVOLIX website coming soon!]

We focus on conditions with large unmet clinical need and limited patient access to effective therapy.

Today, only 17% of the 1.7 million patients eligible for transcatheter aortic valve implantation (TAVI) undergo treatment¹.

Fewer than 5%² of eligible ischemic stroke patients worldwide have access to mechanical thrombectomy, despite stroke being the second leading cause of death and the first cause of acquired handicap³.

For severe mitral valve regurgitation, just 4% of the four million affected patients undergo surgery⁴.

Carvolix develops AI- and imaging-driven mini-robotic technologies designed to expand access to these life-saving procedures. Our platform supports interventional cardiologists in complex procedures, where precision, consistency, and speed are critical.

Our mini-robots operate with supervised autonomy, guided by real-time imaging and artificial intelligence. By assisting with navigation and positioning, they help clinicians manage the most technically demanding steps of valve and stroke interventions, with the goal of improving procedural efficiency, safety, and patient outcomes.

By empowering interventional cardiologists, far more numerous than surgeons and interventional neuroradiologists, and highly receptive to innovation, we expand patients’ access to advanced procedures. Our platform enables a broader base of physicians to perform complex interventions with greater precision, confidence, and reproducibility, ultimately accelerating patient access to life-saving therapies.

REFERENCES:

1. Internal reference, Carvolix – data on file
2. Asif KS, Mokin M, Nogueira RG, et al. Mechanical Thrombectomy Global Access for Stroke (MT-GLASS): A Mission Thrombectomy 2020+ Study. Journal of NeuroInterventional Surgery. 2023;15(6):548–554. doi:10.1136/jnis-2022-019642.
3. French Health Ministry: link to source
4. Internal reference, Carvolix – data on file